NCT05494580 2026-03-10
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
Phase 1/2 Completed
Clinical Trials
12 trialsNCT05824468 2026-03-10
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05824481 2026-03-10
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT03611738 2026-02-09
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04777994 2025-12-23
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Calico Life Sciences LLC
Phase 1 Recruiting
NCT03963544 2025-12-10
METAGIST
Institut Bergonié
Completed
NCT04151342 2025-12-03
CARMA-BROS
University Health Network, Toronto
Recruiting
NCT07219459 2025-10-21
GDFATHERHCC01
CatalYm GmbH
Phase 2 Not yet recruiting
NCT05236946 2025-09-10
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Tata Memorial Hospital
Phase 3 Recruiting
NCT04440267 2025-08-06
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT03958565 2025-05-21
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
University of Colorado, Denver
Recruiting